The discovery of RNAi dates back to the 1990s when researchers observed unexpected gene silencing in plants and fungi. In 1998, Andrew Fire and Craig Mello published a groundbreaking study ...

– Company Expects to Initiate a Phase 1/2 Study for ALN-KHK in Early 2023, with Initial Results Expected in Late 2023 – “We are excited to advance ALN-KHK to the clinic as our first RNAi therapeutic ...

CD Bioparticles announces the launch of comprehensive Extrahepatic RNA Delivery services. NEW YORK, NY, UNITED STATES, ...

A Cornucopia of siRNA- and RNAi-based Therapeutics in Development Show Promise Researchers from academia and industry will present the latest developments in the application of interference RNA (RNAi) ...

The field of RNA-targeted therapeutics is rapidly evolving, offering groundbreaking opportunities for the treatment of a wide array of diseases ...

Advances in genomics and RNA-based technologies are reshaping strategies for insect pest management by enabling the identification and exploitation of ...

Platform combines proprietary AI sequence optimization, novel genetic parts, and lab validation in application-relevant cell models to improve expression and half-life, delivering top candidates in ...

STUART, Fla.--(BUSINESS WIRE)--Cognigenics, a pioneering company in RNA-based therapeutics for neuropsychiatric conditions and neurocognitive disorders, announced the publication of its latest ...

Nicholas Dreisbach (left) is a Senior Associate Scientist in the RNA team at ElevateBio (MA, USA), where he deploys his skills as an expert in capillary gel electrophoresis (CGE) technologies. His ...